Kidney disease
Drug research and approvals for kidney disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,862 studies of kidney disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 85 drug trials for it since 2013, FDA has 2 approved and 22 open orphan designations naming it, and the EU has 10 authorised medicines for it.
- Recruiting worldwide: 1,862
- Trials authorized in Canada: 85
- FDA orphan approvals: 2
- EU medicines: 10
- Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive…NCT07950878 · Not reported · Children's Hospital of Philadelphia · starts Nov 6, 2024
- Six-Channel Wearable ECG for Prediction of Hyperkalemia in Hemodialysis PatientsNCT07947485 · Not reported · Chungnam National University Hospital · starts Nov 12, 2026
- RDN for CKD and Uncontrolled Hypertension TrialNCT07945795 · Not applicable · Beijing Anzhen Hospital · starts Dec 8, 2025
- Histotripsy for Renal Cell CarcinomaNCT07943143 · Not applicable · The University of Hong Kong · starts Oct 13, 2026
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.NCT07937553 · Phase 2 · Kidney Cancer Research Bureau · starts Aug 15, 2025
- Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal…NCT07938515 · Phase 1 · Chendu DIAO Pharmaceutical Group CO., LTD. · starts Nov 2, 2026
- A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal FunctionNCT07938034 · Phase 1 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts Jul 15, 2026
- Intradialytic Benson's Relaxation Technique in Patients With Chronic Kidney DiseaseNCT07935980 · Not applicable · Cairo University · starts Dec 1, 2026
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
Approved 4
- LosartanType-1 angiotensin II receptor antagonist
- BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
- Ethacrynic acidSodium-(potassium)-chloride cotransporter 2 inhibitor
- Aluminum chlorohydrate
Phase 3 12 of 26
- TacrolimusFK506-binding protein 1A inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- CyclosporineCyclophilin A modulator
- Darbepoetin alfaErythropoietin receptor agonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- PrednisoneGlucocorticoid receptor agonist
- AtorvastatinHMG-CoA reductase inhibitor
- CyclophosphamideDNA inhibitor
- AcetaminophenCyclooxygenase inhibitor
- Olmesartan medoxomilType-1 angiotensin II receptor antagonist
Phase 2 12 of 35
- AcetylcysteineGlutathione precursor
- EverolimusFK506-binding protein 1A inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- SugammadexRocuronium sequestering agent
- Efgartigimod alfaIgG receptor FcRn large subunit p51 antagonist
- AliskirenRenin inhibitor
- RamiprilAngiotensin-converting enzyme inhibitor
- TolvaptanVasopressin V2 receptor antagonist
- BasiliximabInterleukin-2 receptor inhibitor
- FebuxostatXanthine dehydrogenase inhibitor
- IohexolDiagnostic agent
Phase 1 or earlier 12 of 171
- SirolimusFK506-binding protein 1A inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- CefepimeBacterial penicillin-binding protein inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- CidofovirHuman herpesvirus 1 DNA polymerase inhibitor
- CisplatinDNA inhibitor
- GanciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- HydrocodoneOpioid receptors; mu/kappa/delta agonist
- PropranololBeta-1 adrenergic receptor antagonist
- QuinineFerriprotoporphyrin IX inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
How its trials ended
4,311 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 910 whose ending is known, 45% met their primary endpoint, 10% missed it and 45% stopped early.
- Completed, result not reported1,83543%
- Ongoing91721%
- Status unknown64915%
- Met its primary endpoint4059%
- Stopped: other or unclear2345%
- Missed its primary endpoint952%
- Stopped: enrollment or feasibility792%
- Stopped: sponsor or business decision501%
- Stopped: lack of efficacy21<1%
- Stopped: funding21<1%
- Stopped: safety5<1%
| Nov 13, 2026 | A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and…EPRA-0322 | Epok Therapeutics Inc. | Pending |
| Jul 30, 2026 | A phase III, randomised, double-blind, study to evaluate the effect of balcinrenone/dapagliflozin compared with dapagliflozin on renal and cardiovascular…Balcinrenone-dapagliflozin (AZD2961) / Dapagliflozin | AstraZeneca Pharmaceuticals | Ongoing |
| May 12, 2026 | A phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the effect of elecoglipron in reducing renal outcomes…Elecoglipron (AZD5004) / Dapagliflozin | AstraZeneca Pharmaceuticals | Ongoing |
| Dec 16, 2025 | Podomount-basket, a phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, pk,…BI 764198 | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Nov 12, 2025 | A phase IIb, randomised, multicentre, double-blind study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat on…Baxdrostat / Dapagliflozin | AstraZeneca Pharmaceuticals | Ongoing |
| Sep 22, 2025 | A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of orforglipron on the incidence of major adverse…Orforglipron (LY3502970) | Eli Lilly | Ongoing |
| Aug 28, 2025 | A phase 2a, open-label, single-arm study to evaluate the efficacy, safety, and pharmacokinetics of VX-407 in subjects with autosomal dominant polycystic kidney…VX-407 | Vertex Pharmaceuticals | Ongoing |
| Jul 30, 2025 | A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets…Empagliflozin | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Mar 27, 2025 | A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-CLS-628 in adult subjects with autosomal…ABBV-CLS-628 | Calico Life Sciences LLC | Ongoing |
| Mar 19, 2025 | A randomised, double blind, placebo-controlled, single ascending dose, phase 1a/1b multi-centre study in healthy participants and participants with autosomal…GSK4771261 | GSK | Ongoing |
| Apr 23, 2018 | JynarqueJYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease… | Otsuka Pharmaceutical Company, Ltd. | Approved |
| Oct 18, 2016 | ZemplarIndicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism… | Abbvie, inc. | Approved |
| Aug 19, 2026 | Eukaryotic ribosome-selective glycosideTreatment of autosomal dominant polycystic kidney disease | Eloxx Pharmaceuticals | Designated |
| Jul 8, 2026 | Human IgG1kappa monoclonal antibody that specifically binds…Treatment of autosomal dominant polycystic kidney disease | AstraZeneca Pharmaceuticals LP | Designated |
| Mar 26, 2026 | TamibaroteneTreatment of autosomal dominant polycystic kidney disease | Rege Nephro Co., Ltd. | Designated |
| Nov 1, 2025 | Fully human IgG1 monoclonal antibody that binds to human…Treatment of autosomal dominant polycystic kidney disease | Calico Life Sciences LLC | Designated |
| Sep 8, 2025 | OctreotideTreatment of autosomal dominant polycystic kidney disease | Camurus AB | Designated |
| Sep 5, 2025 | SalsalateTreatment of autosomal dominant polycystic kidney disease | J & D Pharmaceuticals LLC | Designated |
| Aug 29, 2025 | Anti-PAPPA mAbTreatment of autosomal dominant polycystic kidney disease (ADPKD) | GlaxoSmithKline Research & Development Limited | Designated |
| Feb 12, 2024 | (S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy-1…Treatment of autosomal dominant polycystic kidney disease (ADPKD) | Shanghai Alebund Pharmaceuticals Ltd. | Designated |
| Apr 20, 2023 | OxypurinolTreatment of autosomal dominant polycystic kidney disease | XORTX Therapeutics Inc. | Designated |
| Nov 22, 2022 | MebendazoleTreatment of Autosomal Dominant Polycystic Kidney Disease | Healx Technology Limited | Designated |
| Sep 14, 2022 | Potassium…Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | SCYNEXIS, Inc. | Designated |
| Jun 16, 2022 | A chemically modified full phosphorothioate-backbone…Autosomal dominant polycystic kidney disease (ADPKD) | Novartis Pharmaceuticals Corporation | Designated |
| May 26, 2021 | TesevatinibTreatment of autosomal dominant polycystic kidney disease | Kadmon Corporation | Designated |
| May 29, 2026 | BopediatFurosemide | Proveca Pharma Limited | EMA ↗ |
| Jun 11, 2025 | XoanacylFerric citrate coordination complex | Averoa | EMA ↗ |
| Apr 24, 2023 | VafseoVadadustat | Medice Arzneimittel Pütter GmbH & Co. KG | EMA ↗ |
| Apr 25, 2022 | KapruviaDifelikefalin | Vifor Fresenius Medical Care Renal Pharma France | EMA ↗ |
| Feb 16, 2022 | KerendiaFinerenone | Bayer AG | EMA ↗ |
| Aug 18, 2021 | EvrenzoRoxadustat | Astellas Pharma Europe B.V. | EMA ↗ |
| Nov 11, 2016 | ParsabivEtelcalcetide | Amgen Europe B.V. | EMA ↗ |
| May 27, 2015 | JinarcTolvaptan | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
| Aug 26, 2014 | VelphoroSucroferric oxyhydroxide | Vifor Fresenius Medical Care Renal Pharma France | EMA ↗ |
| Jul 20, 2007 | MirceraMethoxy polyethylene glycol-epoetin beta | Roche Registration GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA